Patents Assigned to Genset S.A.
  • Publication number: 20030162186
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Application
    Filed: May 22, 2002
    Publication date: August 28, 2003
    Applicant: GENSET, S.A.
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • Publication number: 20030157485
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Application
    Filed: November 13, 2001
    Publication date: August 21, 2003
    Applicant: GENSET, S.A.
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • Publication number: 20030148389
    Abstract: The invention relates to polynucleotides of the PAPAP gene, polypeptides encoded by the PAPAP gene, and antibodies directed specifically against such polypeptides. The invention also concerns methods for the treatment or diagnosis of schizophrenia, bipolar disorder or related CNS disorder. The invention also concerns the interaction of PAPAP with schizophrenia candidate gene g34872.
    Type: Application
    Filed: February 6, 2002
    Publication date: August 7, 2003
    Applicant: GENSET, S.A.
    Inventors: Bernard Bihain, Barbara Bour, Lydie Bougueleret
  • Publication number: 20030118997
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Application
    Filed: October 15, 2001
    Publication date: June 26, 2003
    Applicant: GENSET, S.A.
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • Patent number: 6582909
    Abstract: The invention provides novel APM1 genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the APM1 locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Additionally, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. Further, the invention provides diagnostic methods for early detection of obesity-related disorders.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: June 24, 2003
    Assignee: Genset, S.A.
    Inventors: Lydie Bougueleret, Bernard Bihain, Blake Denison, Frances Yen-Potin
  • Patent number: 6579852
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: June 17, 2003
    Assignee: Genset S.A.
    Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
  • Publication number: 20030108882
    Abstract: The present invention is directed to a polynucleotide comprising open reading frames defining a coding region encoding a retinoblastoma binding protein (RBP-7) as well as regulatory regions located both at the 5′ end and the 3′ end of said coding region. The present invention also pertains to a polynucleotide carrying the natural regulation signals of the RBP-7 gene which is useful in order to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory region. The invention also concerns polypeptides encoded by the coding region of the RBP-7 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.
    Type: Application
    Filed: March 19, 2002
    Publication date: June 12, 2003
    Applicant: GENSET, S.A.
    Inventor: Lydie Bougueleret
  • Patent number: 6573068
    Abstract: The sequence of a cDNA encoding Claudin-50 and sequence of Claudin-50 protein are disclosed. The cDNA can be used to express the protein or portions thereof or to obtain antibodies capable of specifically binding to the secreted protein. The cDNA may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNA may also be used to design expression vectors and secretion vectors.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: June 3, 2003
    Assignee: Genset, S. A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret
  • Publication number: 20030099989
    Abstract: The present invention relates to fluorescent probes which can be used in multicolor fluorescence in situ hybridization, and mainly chromosome painting. The probes intended for labeling a chromosome are such that they are composed of a set of DNA segments which are more represented in certain chromosome bands and which are obtained by IRS-PCR amplification from said chromosomes using PCR primers specific for the repeated and dispersed Alu and LINE DNA sequences.
    Type: Application
    Filed: September 19, 2002
    Publication date: May 29, 2003
    Applicant: Genset, S.A.
    Inventor: Dorra Cherif
  • Publication number: 20030100500
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: August 29, 2002
    Publication date: May 29, 2003
    Applicant: Genset S.A.
    Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen, Bernard Bihain
  • Publication number: 20030099965
    Abstract: The present invention relates to a purified or isolated polynucleotide encoding human CIDE B protein, the regulatory nucleic acids contained therein, polymorphic markers thereof, and the resulting encoded protein, as well as to methods and kits for detecting this polynucleotide and this protein. The present invention also pertains to a polynucleotide carrying the natural regulatory regions of the CIDE B gene which is useful, for example, to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory regions.
    Type: Application
    Filed: June 20, 2002
    Publication date: May 29, 2003
    Applicant: GENSET, S.A.
    Inventor: Lydie Bougueleret
  • Publication number: 20030096247
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Application
    Filed: November 14, 2001
    Publication date: May 22, 2003
    Applicant: GENSET, S.A.
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • Patent number: 6566332
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: May 20, 2003
    Assignee: Genset S.A.
    Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen, Bernard Bihain
  • Publication number: 20030092011
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Application
    Filed: November 14, 2001
    Publication date: May 15, 2003
    Applicant: GENSET, S.A.
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • Publication number: 20030092620
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. Adipsin polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, insulin resistance, diabetes, and hypertension.
    Type: Application
    Filed: July 22, 2002
    Publication date: May 15, 2003
    Applicant: GENSET, S.A.
    Inventors: John Lucas, Kristen Briggs
  • Patent number: 6559294
    Abstract: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: May 6, 2003
    Assignee: Genset, S.A.
    Inventors: Remy Griffais, Susan K. Hoiseth, Robert John Zagursky, Benjamin J. Metcalf, Joel A. Peek, Banumathi Sankaran, Leah Diane Fletcher
  • Patent number: 6555316
    Abstract: The invention concerns the human g35030 gene, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the g35030 gene and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: April 29, 2003
    Assignee: Genset S.A.
    Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Laurent Essioux
  • Patent number: 6551792
    Abstract: The present invention concerns, in particular, human flavin-containing monooxygenase 2 (hFMO2), and another human enzyme of the FMO, hFMOx family, their nucleotide and polypeptide sequences. The present invention also concerns vectors for cloning and/or expression containing said nucleotide sequences and cells transformed by these vectors and method for preparing said polypeptides. The invention further concerns methods for selecting compounds and of diagnosing predisposition to pathologies and/or deficiencies related to FMO's and pharmaceutical compositions containing said compounds for treating and/or preventing these pathologies.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: April 22, 2003
    Assignees: Genset, S.A., Institute National de la Sante et de la Recherche Medicale
    Inventors: Marta Blumenfeld, Ilia Tchoumakov, Henri-Jean Garchon, Jean-Francois Bach
  • Patent number: 6548633
    Abstract: The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: April 15, 2003
    Assignee: Genset, S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Jobert
  • Patent number: 6544737
    Abstract: The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: April 8, 2003
    Assignee: Genset S.A.
    Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Annick Cohen-Akenine